Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: margie who wrote (4496)	6/20/1998 10:29:00 AM
From: Bhag Karamchandani	Read Replies (1) of 6136

Margie: What is your assessment of AG3304 Phase I results? Is there a source for more detailed info? In comparison to the AGPH press release, I have come across half a dozen Phase I Cancer drug trial announcements, from various companies, proclaiming reduction or arrest of growth in tumors and metastasis.Are they all guilty of hype? More importantly, is AGPH being too conservative?? What is your reaction to coupling seemingly marginal results with a hint at work on second generation MMP's. Can it be as bleak as it looks, if in fact, unlike Thymatiq, AGPH is spending money on AG3304 Phase II/III trials?? I am unable to determine if the latter include 'non advanced' cancer patients? Since AG 3304 is being administered with two established anticancer drugs why would the latter trials be confined to advanced cases? As most of us have acknowledged, you have been an invaluable source of info on this thread. Hope you can shed some light. Thanks.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next